0000899243-17-018236.txt : 20170713
0000899243-17-018236.hdr.sgml : 20170713
20170713170957
ACCESSION NUMBER: 0000899243-17-018236
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170712
FILED AS OF DATE: 20170713
DATE AS OF CHANGE: 20170713
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: WAVE Life Sciences Ltd.
CENTRAL INDEX KEY: 0001631574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: U0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 CROSS STREET
STREET 2: #10-00
CITY: SINGAPORE
STATE: U0
ZIP: 048424
BUSINESS PHONE: 617-206-4830
MAIL ADDRESS:
STREET 1: 8 CROSS STREET
STREET 2: #10-00
CITY: SINGAPORE
STATE: U0
ZIP: 048424
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences Ltd.
DATE OF NAME CHANGE: 20151106
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences LTD.
DATE OF NAME CHANGE: 20151106
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences Pte Ltd
DATE OF NAME CHANGE: 20150123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Panzara Michael A.
CENTRAL INDEX KEY: 0001679039
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37627
FILM NUMBER: 17964062
MAIL ADDRESS:
STREET 1: 733 CONCORD AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-07-12
0
0001631574
WAVE Life Sciences Ltd.
WVE
0001679039
Panzara Michael A.
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
CAMBRIDGE
MA
02138
0
1
0
0
Franchise Lead, Neurology
Ordinary Shares
2017-07-12
4
S
0
7414
16.6738
D
15336
D
On July 12, 2017, the reporting person sold 7,414 ordinary shares solely to cover taxes associated with the vesting of restricted share units on July 11, 2017. These sales were made pursuant to a 10b5-1 Trading Plan entered into solely for the purpose described in the prior sentence.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.55 to $16.95 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
/s/ Michael A. Panzara
2017-07-13